Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Carboplatin
Drug ID BADD_D00364
Description Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma.[L32253] Early clinical studies of carboplatin were performed in 1982.[A230523] Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.[L32248]
Indications and Usage For the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of PARAPLATIN and cyclophosphamide. It is also indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin.
Marketing Status Prescription; Discontinued
ATC Code L01XA02
DrugBank ID DB00958
KEGG ID D01363
MeSH ID D016190
PubChem ID 426756
TTD Drug ID D0X7HM
NDC Product Code 0703-4239; 55150-335; 63592-0271; 68083-192; 49812-0010; 68554-0084; 53104-7570; 69448-005; 0703-4246; 54875-0002; 55150-386; 55150-334; 0703-4248; 55150-333; 63323-172; 72659-863; 68083-191; 71288-100; 16729-295; 0703-4244; 68083-193; 68083-190; 61703-339
Synonyms Carboplatin | cis-Diammine(cyclobutanedicarboxylato)platinum II | CBDCA | Paraplatin | Paraplatine | Platinwas | Ribocarbo | Carboplat | Neocarbo | Carbosin | Carbotec | Ercar | JM-8 | JM 8 | JM8 | Nealorin | NSC-241240 | NSC 241240 | NSC241240 | Blastocarb
Chemical Information
Molecular Formula C6H12N2O4Pt
CAS Registry Number 41575-94-4
SMILES C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Facial paralysis17.04.03.0080.001066%Not Available
Failure to thrive19.07.05.001; 18.04.01.003; 14.03.02.0080.000556%Not Available
Fanconi syndrome03.06.01.001; 20.05.03.009; 14.01.01.0110.001598%Not Available
Fatigue08.01.01.002--
Febrile neutropenia08.05.02.004; 01.02.03.0020.031436%
Feeling abnormal08.01.09.014--Not Available
Feeling hot08.01.09.0090.012255%Not Available
Fibrin D dimer increased13.01.02.0360.000533%Not Available
Fibrosis08.03.01.0010.001066%Not Available
Fistula15.03.02.0010.000533%Not Available
Flank pain20.02.03.006; 15.03.04.003; 08.01.08.0070.001066%
Flushing23.06.05.003; 24.03.01.002; 08.01.03.0250.031170%
Formication17.02.06.018; 19.10.02.0100.001598%Not Available
Frequent bowel movements07.02.04.002--Not Available
Gait disturbance17.02.05.016; 08.01.02.002--
Gastric ulcer07.04.03.0020.000799%
Gastrooesophageal reflux disease07.02.02.003--
Gastroenteritis11.01.07.004; 07.19.03.0010.000799%Not Available
Gastroenteritis viral11.05.04.005; 07.19.03.0050.001332%Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal haemorrhage07.12.02.001; 24.07.02.009--Not Available
Gastrointestinal necrosis24.04.08.006; 07.15.01.0030.000347%
Gastrointestinal pain07.01.05.005--
Gastrointestinal perforation07.04.04.0010.000278%Not Available
Generalised oedema14.05.06.007; 08.01.07.0040.000533%
Generalised tonic-clonic seizure17.12.01.002--Not Available
Gingival disorder07.09.03.0010.000533%Not Available
Glioma17.20.01.004; 16.30.01.0040.001066%Not Available
Glomerulonephritis rapidly progressive20.05.01.004; 10.04.04.0080.000533%Not Available
Granulocytopenia01.02.03.0030.000799%Not Available
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 25 Pages